ClinicalTrials.gg
Status unknownNCT05187793RESETUpdated Feb 13, 2023

Study of Efficacy of Different Treatment Regimens of Olokizumab

A Phase 3 interventional study of Olokizumab and Standard therapy in COVID-19, sponsored by R-Pharm. Status unknown at 5 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-13.

Sponsored by R-Pharm · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2023), so the status shown — last known as Active, not recruiting — may be out of date.

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jul 2021, registered Dec 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 144 studies in COVID-19 with a site in Russian Federation — 4 open to participants now, 9 under way, 1 of them phase 3. COVID-19 · Russian Federation.

Enrollment
53rd of 105
198 · median 198
Started
2021
with 37 others
Phase 3
40 of 144
none open now
Registered
109th of 144
by date

Among the 144 studies in COVID-19 with a site in Russian Federation, this one is the 53rd largest by enrollment of the 105 interventional ones that give a count, is one of 38 that started in 2021, is one of 40 in phase 3, and was the 109th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 144 studies in COVID-19 with a site in Russian Federation are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in COVID-19 with a site in Russian Federation, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the efficacy and safety of Artlegia (INN: olokizumab) new dosing regimen in patients with moderate coronavirus infection (COVID-19) with signs of hyperinflammation.

This study is a multicentre, open-label, randomized, comparative, parallel group, active-controlled clinical trial.

Read the detailed description

The study has an adaptive design. According to the initial calculation of the sample size it was planned to include about 204 patients in the study. After interim analyzing of the data of the first 100 randomized patients a decision about the final sample size was made. The size of the intent-to-treat (ITT) population for the final efficacy analysis at the primary endpoint is 180 patients. Taking into account the probability of dropping out up to 10% of patients, 198 patients were planned to be randomized into the study, no more than 220 patients were planned to be screened.

The study will include the following periods:

  • Screening period lasting up to 2 days (days -1-0). During this period patient's eligibility assessment will be performed;
  • Treatment period: up to 10 days. Treatment period starts from the end of the screening (days 1-10) and includes randomization following by a 10 days of standard therapy with or without olokizumab and patient monitoring (laboratory tests, electrocardiogram (ECG), chest computed tomography (CT));
  • Short-term follow-up period up to 28 days (days 11 through 28). It includes procedures of patient monitoring (laboratory tests, ECG, chest CT) on days 14 (± 2) and 28 (± 2).
  • Long-term follow-up period: up to 180 days (days 29 through 180). Includes telephone contacts with the patient on days 45, 60, 90 and 180.

Eligible patients will be randomized to one of 2 treatment groups to receive olokizumab (OKZ) 128 mg i.v. infusion (one or two single doses) against the background of standard therapy, or standard therapy alone.

In OKZ group study drug olokizumab 128 mg is administered as a single intravenous infusion. A comprehensive assessment of the clinical and laboratory response is performed daily within 5 days (120 hours) after the first injection. If there is no response to therapy or the response is insufficient, the repeated dose of OKZ, 128 mg, is administered.

As standard anti-inflammatory therapy, patients in both groups will receive baricitinib (at the standard recommended dose of 4 mg / 1 time per day, for 7 days) and low doses of glucocorticosteroids (dexamethasone at doses of 4-20 mg / day or methylprednisolone at a dose of 1 mg / kg / intravenous injection every 12 hours).

With an observed clinical deterioration (fever increase, dyspnea, oxygen saturation decrease, the appearance / increase in the need for oxygen support) after repeated infusion of OKZ in the main group (at least 24 hours from the first infusion started), or after 24 hours or more from the start of therapy in the comparison group, the patient is considered "not responding" to therapy and requiring another anti-inflammatory treatment regimens.

Standard therapy also includes etiotropic therapy for COVID-19, as well as symptomatic and anticoagulant therapy.

Etiotropic therapy. Favipiravir will be used in recommended dosage regimens according to temporary guidelines "Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)" of the Ministry of Health of Russian Federation.

Patients who have started etiotropic therapy with favipiravir or remdesivir prior to randomization will continue the initiated treatment.

Сlinical status will be assessed daily in the first 10 days, then on days 14, 21, 28, 45, 60, 90 and 180, vital signs - three times daily in the first 5 days, once daily on days 6-10, then on days 14 and 28, chest CT - on days 7, 14 and 28; laboratory parameters - on days 1 - 5, 10, 14, 28.

On day 7 primary endpoint of patient's clinical recovery (defined as score of 3 or less on a 10-point ordinal scale of clinical improvement) will be assessed. The last patient's visit to the study site will be the visit on Day 28. On Days 45, 60, 90 and 180 the phone follow-up will be performed.

In olokizumab group, eligible subjects will be selected to participate in pharmacokinetic analysis. Blood samples for the evaluation of olokizumab pharmacokinetics will be taken before the infusion of olokizumab and in 2 h, 4 h, 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 144 h, 168 h, 192 h, 216 h, 240 h, 336 h and 672 h after the first administration of the drug (since the start of infusion).

Expected study duration for each patient will be 182 (± 2) days, including screening periods (2 days), therapy and short-term follow-up (28 (± 2) days), and long-term extended follow-up (152 (± 2) 2 days).

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • SARS-CoV-2
  • 2019-nCoV
  • Severe acute respiratory syndrome coronavirus 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed for participation in this study.
  2. Hospitalization (no more than 72 hours prior to randomization) with a diagnosis of coronavirus infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus (COVID-19).
  3. Moderate COVID-19. Moderate course of the disease is characterized by pneumonia on chest computed tomography (CT) (CT-1,2 stages) and body temperature > 38 °C, in combination with 1 or more of the following:

    • SpO2 \<95%,
    • respiratory rate > 22,
    • dyspnea on exertion,
    • C-reactive protein (CRP) level> 10 mg / l,
    • one of the following risk factors: diabetes mellitus, severe cardiovascular disease, chronic renal failure, cancer, obesity, or age ≥ 65 years.
  4. The presence of signs of hyperinflammation. Signs of hyperinflammation are body temperature ≥ 38 °C for 2 days or more, combined with 1 or more of the following:

    • CRP level > 3 Upper Normal Limit (UNL),
    • White blood cell count - 2.0-3.5 × 10\^9 / l,
    • Absolute lymphocyte count - 1.0-1.5 × 10\^9 / l
  5. Infection caused by the SARS-CoV-2 confirmed by of Polymerase chain reaction (PCR) test or an express test for antigen / antibodies to SARS-CoV-2 framework of the protocol.
  6. Ability to follow protocol requirements and perform all clinical trial procedures.
  7. The willingness of the participants and their sexual partners to use reliable methods of , during the entire study and at least 3 months after the treatment completion. This requirement does not apply to participants who have undergone surgical sterilization as well as to women with permanent cessation of menstruation, which should be determined retrospectively after 12 months of natural amenorrhea, i.e. amenorrhea with an appropriate clinical status (eg, appropriate age). Reliable methods of contraception involve the use of one barrier method in combination with one of the following: spermicides, intrauterine spiral/oral contraceptives in a sexual partner.
  8. Willingness not to drink alcohol during the entire study.

Additional inclusion criteria for the pharmacokinetics (PK) subgroup:

  1. Signed informed consent to participate in the additional study of pharmacokinetics.
  2. 18.5 - 35.0 kg/m2.
  3. The ability of the patient, by the opinion of the investigator, to participate in the additional study of pharmacokinetics and to provide the required number of blood samples.

Exclusion criteria

Exclusion Criteria:

  1. to olokizumab and / or other components of the study drug.
  2. to favipiravir or glucocorticosteroids or Janus kinase inhibitors (baricitinib).
  3. Signs of a severe or extremely severe course of COVID-19, such as:

    • altered level of consciousness, agitation,
    • the need for / use of Non-invasive ventilation (NIV) / Adaptive lung ventilation (ALV) / Extracorporeal membrane oxygenation (ECMO) at screening,
    • hemodynamic instability eg systolic blood pressure \< 90 mm Hg or diastolic blood pressure \< 60 mm Hg and urine output less than 20 ml / hour,
    • CT-3,4 stage on chest CT, signs of Acute respiratory distress syndrome (ARDS),
    • arterial blood lactate > 2 mmol / l,
    • quick Sequential Organ Failure Assessment (qSOFA) > 2 points.
  4. Any of the following laboratory abnormalities:

    • \<80 g / l,
    • \<0.5 x 10\^9 / l,
    • White blood cell count \<2.0 x 10\^9 / l,
    • count \<50 x 10\^9 / l,
    • (ALT) and / or Aspartate aminotransferase (AST) ≥ 3.0 x UNL.
  5. Severe renal failure: \< 30 ml / min.
  6. Confirmed sepsis with non-COVID-19 pathogens and procalcitonin levels > 0.5 ng / ml.
  7. Prior and / or C virus infection.
  8. High probability of disease progression to death within the next 24 hours, regardless of therapy, by the opinion of the investigator.
  9. Concomitant diseases associated with a poor prognosis (with the exception of those listed in inclusion criteria No. 3: diabetes mellitus, severe cardiovascular disease, chronic renal failure, cancer, obesity, or age ≥ 65 years).
  10. therapy for organ transplantation.
  11. Recent (less than 5 half-lives) or prescribed at screening:

    • Olokizumab (use or prescription prior to study randomization);
    • Biological drugs with immunosuppressive effects, including, but not limited to:Interleukin 1 (IL-1) inhibitors (anakinra, canakinumab), IL-6 receptor inhibitors (tocilizumab, sarilumab, levilimab), IL-17 (secukinumab, netakimab), tumor necrosis factor α inhibitors (TNFα) (infliximab, adalimumab, etanercept, etc.), anti-B-cell drugs, and others;
    • Immunosuppressive drugs (including, but not limited to):

      • in high doses (> 1 mg / kg prednisolone equivalent) orally or parenterally;
      • Janus kinase (JAK) kinase inhibitors;
      • cyclophosphamide, etc.
  12. History of active tuberculosis or suspected active tuberculosis.
  13. Simultaneous participation in another clinical trial.
  14. Pregnancy or breastfeeding at screening; planning pregnancy during the entire study and within 3 months after the completion of treatment.
  15. Any information from anamnesis that may lead to a complicated interpretation of the study results or create additional risk for the patient as a result of participation in the study.
  16. Known (from history) or suspected abuse of alcohol, psychotropic drugs; drug addiction.
  17. Subjects with a history or presence of any psychiatric disorder(s).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
198 participants (actual)

Study arms

  • Experimental
    Olokizumab

    Subject randomized to receive intravenous infusion of 0,8 ml solution of Olokizumab, one (128 mg), or two (256 mg) doses, in addition to standard therapy in line with the current temporary guidelines "Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)" of the Ministry of Health of Russian Federation. Standard therapy includes: * Baricitinib, p.o., 4 mg once daily for 7 days * Favipiravir, p.o., * for patients weighing \<75 kg: 1600 mg twice daily on Day 1, then 600 mg twice daily from the 2nd to the 10th day; * for patients weighing ≥ 75 kg: 1800 mg twice daily on Day 1, then 800 mg twice daily from the 2nd to the 10th day; (Patients who have started etiotropic therapy with favipiravir or remdesivir prior to randomization will continue the initiated treatment.) * dexamethasone at doses of 4 - 20 mg / day or methylprednisolone at a dose of 1 mg / kg / intravenous injection every 12 hours.

    Drug: Olokizumab · Drug: Standard therapy

  • Active comparator
    Standard therapy

    Standard therapy in line with the current temporary guidelines "Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)" of the Ministry of Health of Russian Federation including: * Baricitinib, p.o., 4 mg once daily for 7 days * Favipiravir, p.o., * for patients weighing \<75 kg: 1600 mg twice daily on Day 1, then 600 mg twice daily from the 2nd to the 10th day; * for patients weighing ≥ 75 kg: 1800 mg twice daily on Day 1, then 800 mg twice daily from the 2nd to the 10th day; (Patients who have started etiotropic therapy with favipiravir or remdesivir prior to randomization will continue the initiated treatment.) * dexamethasone at doses of 4 - 20 mg / day or methylprednisolone at a dose of 1 mg / kg / intravenous injection every 12 hours.

    Drug: Standard therapy

Interventions

  • Olokizumab, 128 mg, solution for subcutaneous administration 160 mg/mL

  • DrugStandard therapy

    Standard treatment including: * Baricitinib, 4 mg, film coated tablets * Favipiravir, 200 mg, film coated tablets * Dexamethasone IV or IM OR Methylprednisolone IV

06

What researchers measure

Primary outcomes

  1. Clinical recovery rate at day 7

    Clinical recovery defined as score of 3 or less on a 10-point ordinal scale of clinical improvement. (From 0 "Healthy - no clinical manifestations, no viral RNA detected" to 10 "Death".) 7 days are counted from the day of the first administration / intake of study therapy / comparison therapy, depending on study group. Criteria for transition from category "4" to category "3" (criteria for potential discharge): body temperature \< 37 °C; respiratory rate ≤ 20 per minute; SpO2 ≥ 95% without oxygen support, CRP \< 10 mg/l. If any emergency procedures should be prescribed and/or signs of progression on CT are detected, the patient cannot be discharged/transferred to category "3". (In the case of the "rescue" therapy use or the development of clinical deterioration (an increase in the score by 1 point or more) during the follow-up period in a previously recovered patient, the patient is not considered as a "responder", i.e., who has reached the primary endpoint.)

    Time frame: Up to day 7

Secondary outcomes

  1. Rate of clinical deterioration by at least 1 point from the baseline ordinal score at day 28, depending on study group

    Rate of clinical deterioration by at least 1 point from the baseline ordinal score at day 28, depending on study group

    Time frame: Up to day 28

  2. CRP normalization rate

    Normalization is defined as CRP blood level within normal range (\< 10 mg/l), assessed on days 5, 10, 14, 28, depending on study group.

    Time frame: Up to Day 28

  3. Ferritin normalization rate

    Normalization is defined as ferritin blood level within normal range, assessed on days 5, 10, 14, 28, depending on study group.

    Time frame: Up to Day 28

  4. D-dimer normalization rate

    Normalization is defined as D-dimer blood level within normal range, assessed on days 5, 10, 14, 28, depending on study group.

    Time frame: Up to Day 28

  5. Mean CRP levels

    Mean CRP levels assessed on days 5, 10, 14, 28, depending on study group

    Time frame: Up to Day 28

  6. Mean ferritin levels

    Mean ferritin levels assessed on days 5, 10, 14, 28, depending on study group

    Time frame: Up to Day 28

  7. Mean D-dimer levels

    Mean D-dimer levels assessed on days 5, 10, 14, 28, depending on study group

    Time frame: Up to Day 28

  8. Rate of prescribing other anti-inflammatory therapy regimens (rescue therapy), depending on study group

    Rate of prescribing other anti-inflammatory therapy regimens (rescue therapy), depending on study group

    Time frame: Up to day 28

Other outcomes

  1. Rate of clinical deterioration by at least 1 point from the baseline ordinal score at day 7, depending on study group

    Rate of clinical deterioration by at least 1 point from the baseline ordinal score at day 7, depending on study group

    Time frame: Up to day 7

  2. Clinical recovery rate at day 14

    Clinical recovery defined as score of 3 or less on a 10-point ordinal scale of clinical improvement, 14 days are counted from the day of the first administration / intake of study / comparison therapy by treatment group

    Time frame: Up to day 14

  3. Cumulative incidence of transfer to intensive care unit (ICU), transfer to mechanical ventilation, development of ARDS and / or death, at day 28

    Cumulative incidence of transfer to ICU, transfer to mechanical ventilation, development of ARDS and / or death, at day 28

    Time frame: Uo to day 28

  4. Incidence of progression on chest CT at day 28

    Incidence of progression on chest CT at day 28, depending on study group

    Time frame: Up to day 28

  5. Rate of transfer to ICU at day 28

    Rate of transfer to ICU at day 28, depending on study group

    Time frame: Up to day 28

  6. Rate of transfer to mechanical ventilation at day 28

    Rate of transfer to mechanical ventilation at day 28, depending on study group

    Time frame: Up to day 28

  7. Incidence of ARDS at day 28

    Incidence of ARDS at day 28, depending on study group

    Time frame: Up to day 28

  8. Incidence of death from any cause at day 28

    Incidence of death from any cause at day 28, depending on study group

    Time frame: Up to day 28

  9. Incidence of symptoms of a secondary bacterial infection

    * leukocytosis \> 12x10\^9 / l (in the absence of previous use of glucocorticosteroids), * and / or shift to stab \> 10 %, * and / or purulent sputum or other clinical manifestations of purulent inflammation, * and / or an increase in procalcitonin\> 0.5 ng / ml depending on study group

    Time frame: Up to day 28

  10. Time to improvement in clinical status by at least 1 point

    Time to improvement in clinical status by at least 1 point (from the moment of drug administration) (median, in days), depending on study group

    Time frame: from the moment of drug administration to improvement, up to 28 days

  11. Incidence of improvement in clinical status by at least 1 point on days 3, 5, 7, 10, 14, 21, 28, depending on study group

    Incidence of improvement in clinical status by at least 1 point on days 3, 5, 7, 10, 14, 21, 28, depending on study group

    Time frame: Up to day 28

  12. Time to reach SpO2 ≥ 95%, without oxygen support for 2 consecutive days

    Time to reach SpO2 ≥ 95%, without oxygen support for 2 consecutive days (from the moment of drug administration) (median, in days), depending on study group

    Time frame: from the moment of drug administration to the moment when SpO2 ≥ 95%, up to 28 days

  13. Duration of hospitalization at day 28

    Duration of hospitalization at day 28 (from the moment of drug administration) (median, in days), depending on study group

    Time frame: from the moment of drug administration to discharge, up to 28 days

  14. Duration of ICU stay at day 28

    Duration of ICU stay at day 28 (from the moment of drug administration) (median, in days), depending on study group

    Time frame: from the moment of drug administration to discharge from ICU, up to 28 days

  15. Time to normalization of temperature

    Time to normalization of temperature (body temperature less than 37 °C for 48 hours or more, without taking antipyretics) (from the moment of drug administration) (median, in days), depending on study group

    Time frame: from the moment of drug administration to temperature normalization, up to 28 days

  16. Change from baseline of the assessment of the immune status by the Investigator

    Change from baseline of the assessment of the immune status by the Investigator, based on clinical course and laboratory markers (- IL-6, - complement components - C3 and C4, T-lymphocytes (CD3 + CD19-); T - helpers (CD3 + CD4 + ); T - cytotoxic lymphocytes (CD3 + CD8); Immunoregulatory index (T-helpers / T-cytotoxic), (CD3 + CD4 + / CD3 + CD8 +); B - lymphocytes (CD3-CD19 +); Activated T-lymphocytes with phenotype (CD3 + HLA-DR +); Lymphocytes with HLA-DR + phenotype, NK cells total (CD3- CD16 + CD56 +); Activated T-cells with markers of NK cells (CD3 + CD56 +).

    Time frame: Baseline, day 28

07

Study locations

5 sites
  • State Budgetary Healthcare Institution "City Clinical Hospital named after F.I. Inozemtsev of Moscow Healthcare Department"
    Moscow, 105187, Russian Federation
  • Federal State Budgetary Institution "Central Clinical Hospital with a Polyclinic" of Presidential Administration of the Russian Federation
    Moscow, 121359, Russian Federation
  • State Budgetary Healthcare Institution "City Clinical Hospital № 52 of Moscow Healthcare Department"
    Moscow, 123182, Russian Federation
  • State Budgetary Healthcare Institution "Infectious Diseases Hospital No. 1 of Moscow Healthcare Department"
    Moscow, 125367, Russian Federation
  • State Budgetary healthcare Institution of the Voronezh region "Voronezh Regional Clinical Hospital No. 1"
    Voronezh, 394066, Russian Federation
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Oct 2022, 15 months.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 15 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2021
First posted
Jan 12, 2022
StartActual
Jul 8, 2021
Primary completionActual
Oct 31, 2022
CompletionEst.
Apr 2023
Last update
Feb 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05187793
Lead sponsor
R-Pharm
Collaborators
Federal Budget Institution of Science "Central Research Institute of Epidemiology" of the Rospotrebnadzor, Group of companies Medsi, JSС
Responsible party
Sponsor
First posted
Jan 12, 2022
Start date
Jul 8, 2021
Primary completion
Oct 31, 2022
Completion
Apr 2023 (estimated)
Last update
Feb 13, 2023

Study contacts

Mikhail Samsonov
study director · R-Pharm

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olokizumab

Start the discussion